Barclays Maintains Equal-Weight Rating on Medpace, Raises Target to $675
Barclays raised its price target on Medpace to $675 per share from $625 while maintaining its Equal-Weight rating.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results.
Barclays maintains Medpace at equal weight
Barclays maintained its equal-weight rating on Medpace Holdings, according to Benzinga’s ratings-action recap.